Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System
DOI: https://doi.org/10.2147/ijn.s460844
IF: 7.033
2024-06-11
International Journal of Nanomedicine
Abstract:Haiqing Wang, 1, &ast Wentao Bo, 1, &ast Xielin Feng, 1 Jinliang Zhang, 1 Ge Li, 2 Yan Chen 3 1 Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People's Republic of China; 2 Department of Emergency, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People's Republic of China; 3 Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan Chen; Ge Li, Email ; ; Lenvatinib (LVN) is a potentially effective multiple-targeted receptor tyrosine kinase inhibitor approved for treating hepatocellular carcinoma, metastatic renal cell carcinoma and thyroid cancer. Nonetheless, poor pharmacokinetic properties including poor water solubility and rapid metabolic, complex tumor microenvironment, and drug resistance have impeded its satisfactory therapeutic efficacy. This article comprehensively reviews the uses of nanotechnology in LVN to improve antitumor effects. With the characteristic of high modifiability and loading capacity of the nano-drug delivery system, an active targeting approach, controllable drug release, and biomimetic strategies have been devised to deliver LVN to target tumors in sequence, compensating for the lack of passive targeting. The existing applications and advances of LVN in improving therapeutic efficacy include improving longer-term efficiency, achieving higher efficiency, combination therapy, tracking and diagnosing application and reducing toxicity. Therefore, using multiple strategies combined with photothermal, photodynamic, and immunoregulatory therapies potentially overcomes multi-drug resistance, regulates unfavorable tumor microenvironment, and yields higher synergistic antitumor effects. In brief, the nano-LVN delivery system has brought light to the war against cancer while at the same time improving the antitumor effect. More intelligent and multifunctional nanoparticles should be investigated and further converted into clinical applications in the future. Keywords: lenvatinib, nano-drug delivery system, antitumor, side effects, diagnosis Graphical Cancer remains the most common disease and one of the leading causes of death due to a high incidence and late diagnosis. The commonly used treatment methods include surgery, radiotherapy, chemotherapy, targeting therapy, and immunotherapy. With advances in targeted therapeutics, survival rates have significantly improved for numerous advanced-stage cancers, including hepatocellular carcinoma (HCC), colorectal cancer and gastric cancer. Lenvatinib (LVN), as a multiple-targeted receptor tyrosine kinase inhibitor, 1–3 has been approved for several cancers by the American Food and Drug Administration, including HCC, 4 thyroid cancer 5 and metastatic renal cell carcinoma. 6 In a Phase 2 randomized, open, multicenter trial, 6 LVN was administered orally, alone or with everolimus, for treatment of progressive metastatic renal cell carcinoma as second-line treatment. The overall survival was not significantly different, LVN alone or combined with everolimus groups had a higher objective response rate and longer progression-free survival. Besides, LVN also showed clinical effect for refractory thyroid cancer. In a Phase 3 randomized, double-blind, multicenter trial, LVN treatment group demonstrated 18.3 months of median progression-free survival, while the placebo group only had 3.6 months of median progression-free survival for patients with radioiodine refractory thyroid cancer. LVN treatment group also had a higher objective response rate (64.8% versus 1.5%). 5 In the RELECT study, LVN was shown to be non-inferior to sorafenib with similar survival after treating advanced unresectable HCC patients, thus has been recommended as an optional first-line treatment for unresectable advanced HCC. 4 The median survival for LVN treatment group was 13·6 months, which was similar to the sorafenib group with 12.3 months. As such, LVN alone has superior antitumor efficacy in clinical practice with greater potential for combination therapy. The combined LVN and immunopharmacology pembrolizumab treatment showed potential antitumor activity, causing significant survival benefits compared to L -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology